Pangaea Data Enters Collaboration with Sanofi to Improve Detection of AATD Through AI-Driven Clinical Decision Support

Press Release: Pangaea Expands its AI Platform to Support Decision-Making & Guideline-Concordance for MDT Tumor Boards Across Enterprise & Community Care

Microsoft & NVIDIA Documentary: Pangaea Data Closing Care Gaps

GO BACK

Finding Undiagnosed Cancer Cachexia Patients Using Guideline-based AI

4:30 – 5:30 PM CET, November 17th, 2026, City Cube - Messe Berlin, Germany

Poster Presentation

Learn how, in collaboration with NHS Lothian, Pangaea’s AI platform was configured on four cachexia guidelines (Fearon, Evans, GLIM and mGPS criteria) and outperformed baseline LLM prompting, achieving 100% precision and 92.3% sensitivity for identifying patients with undiagnosed cancer cachexia and 89.7% precision and 96.3% sensitivity for documented  cancer cachexia. 

The results demonstrate that embedding guidelines directly into the AI, patient records can be systematically assessed without clinician prompting, generating repeatable, actionable insights to support timely clinical assessment and intervention.

Register to Meet Us

Presenters

Markus Vogel, MD, MBA
Visiting Researcher,
Charité – Universitätsmedizin Berlin
Monica Mok
Project Manager,
Pangaea Data